Text Size

Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr Koren Ariel, HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00736060
First received: August 14, 2008
Last updated: August 25, 2011
Last verified: August 2011
History of Changes
  Purpose

This study will summarized the clinical and laboratory data and the outcome of all the patients suffering from Sickle Cell Anemia (Including Sickle cell thalassemia) admitted to the pediatric ward.


Condition Intervention
Sickle Cell Anemia
Sickle Cell Thalassemia
 Other: Observational

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Study the Clinical and Laboratory Characteristics and the Outcome of Sickle Cell Anemia Patients Admitted to the Pediatric Ward Because of Fever as the Presenting Symptom

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by HaEmek Medical Center, Israel:

Estimated Enrollment: 60
Study Start Date: May 2008
Study Completion Date: November 2008
Groups/Cohorts Assigned Interventions
1
Sickle cell anemia
 Other: Observational
Summary of clinical and laboratory data
2
Sickle cell thalassemia
 Other: Observational
Summary of clinical and laboratory data

Detailed Description:

The actual protocol for SCA patients admitted with fever is to obtain blood cultures and start empiric antibiotic treatment.

The study cohort included 60 SCA patients actually treated in the Pediatric Hematology Unit.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

60 patients treated at the Pediatric Hematology Unit in the Ha'Emek Medical Center suffering from sickle cell anemia or sickle cell thalassemia admitted with fever as the presenting symptom.

Criteria

Inclusion Criteria: All patients admitted with fever as the only presenting symptom.

Exclusion Criteria: Patients admitted with another causes related or unrelated to sickle cell disease and have also fever.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00736060

Locations
Israel
Pediatric Hematology Unit - Ha'Emek Medical Center
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: Carina Levin, MD Pediatric Hematology Unit - Ha'Emek Medical Center - Afula - 18101 - Israel
Principal Investigator: Ilena Arshinov, MD Pediatric Dpt B - Ha'Emek Medical Center - Afula - Israel
  More Information

No publications provided

Responsible Party: Dr Koren Ariel, Head of Pediatric Hematology Unit and Pediatric Dpt B, HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT00736060     History of Changes
Other Study ID Numbers: 0027-08-EMC
Study First Received: August 14, 2008
Last Updated: August 25, 2011
Health Authority: Israel: Ministry of Health

Keywords provided by HaEmek Medical Center, Israel:
Fever
Blood cultures

Additional relevant MeSH terms:
Anemia
Anemia, Sickle Cell
Thalassemia
Hematologic Diseases
 Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on June 18, 2013